Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants
In a double‑blind, placebo‑controlled crossover study in 22 healthy adults, continuous DMT infusions showed dose‑proportional pharmacokinetics and rapidly produced dose‑dependent subjective effects that plateaued after 30 minutes with a ceiling for positive effects at 1.8 mg/min, whereas 2.4 mg/min increased anxious ego dissolution and anxiety and produced moderate acute tolerance. A self‑guided titration enabled participants to achieve effects comparable to the 1.8 mg/min dose, supporting dose‑finding and adjustable dosing strategies for future DMT research.
Authors
- Matthias Liechti
- Nikhil Varghese
- Andreas Eckert
Published
Abstract
N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that is known for its short-lasting effects when administered intravenously. Several studies have investigated the administration of intravenous boluses or combinations of a bolus and a subsequent continuous infusion. However, data on dose-dependent acute effects and pharmacokinetics of continuous DMT infusions are lacking. We used a double-blind, randomized, placebo-controlled, crossover design in 22 healthy participants (11 women, 11 men) who received placebo and DMT (0.6, 1.2, 1.8, and 2.4 mg/min) over an infusion duration of 120 min. We also tested a self-guided titration scheme that allowed participants to adjust the DMT dose rate at prespecified time points to achieve their desired level of subjective effects. Outcome measures included subjective effects, autonomic effects, adverse effects, plasma hormone concentrations, and pharmacokinetics up to 3 h after starting the infusion. DMT infusions exhibited dose-proportional pharmacokinetics and rapidly induced dose-dependent subjective effects that reached a plateau after 30 min. A ceiling effect was observed for “good drug effect” at 1.8 mg/min. The 2.4 mg/min dose of DMT induced greater anxious ego dissolution than the 1.8 mg/min dose and induced significant anxiety compared with placebo. We observed moderate acute tolerance to acute effects of DMT. In the self-guided titration session, the participants opted for moderate to strong psychedelic effects, comparable in intensity to the 1.8 mg/min DMT dose rate in the randomized dosing sessions. These results may assist with dose finding for future DMT research and demonstrate that acute subjective effects of DMT can be rapidly adjusted through dose titration.
Research Summary of 'Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants'
Introduction
N,N-dimethyltryptamine (DMT) is a short-acting serotonergic psychedelic whose acute psychoactive effects are primarily mediated at 5-HT2A receptors. Prior clinical work has most commonly delivered DMT by intravenous bolus or by combining a bolus with a continuous infusion; boluses tend to produce very rapid, intense and sometimes poorly tolerated effects, whereas some continuous infusions without a bolus have produced milder, gradually stabilising effects. However, dose-dependent acute effects and detailed pharmacokinetics of longer continuous DMT infusions across a range of infusion rates remain poorly characterised, and formal testing of within-session self-titration has not been reported in a controlled setting. Erne and colleagues therefore designed a double-blind, placebo-controlled, within-subject crossover study to map acute subjective, autonomic, endocrine and pharmacokinetic responses to four continuous intravenous DMT infusion rates (0.6, 1.2, 1.8 and 2.4 mg/min) administered over 120 min, and to evaluate a subsequent open-label, self-guided titration session in which participants could adjust dose rate at prespecified times to reach a desired level of subjective effect. The study aimed to inform dose selection for future research and to test whether acute subjective states can be rapidly and safely modulated by within-session dose adjustment.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Erne, L., Vogt, S. B., Müller, L., Nuraj, A., Becker, A., Klaiber, A., Zuparic, M., Varghese, N., Eckert, A., Rudin, D., Luethi, D., & Liechti, M. E. (2025). Acute dose-dependent effects and self-guided titration of continuous N,N-dimethyltryptamine infusions in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacology, 50(6), 1008-1016. https://doi.org/10.1038/s41386-024-02041-8
References (22)
Papers cited by this study that are also in Blossom
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Vogt, S. B., Ley, L., Erne, L. et al. · Translational Psychiatry (2023)
Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)
D’Souza, D. C., Syed, S. A., Safi-Aghdam, H. et al. · Neuropsychopharmacology (2022)
Good, M., Joel, Z., Benway, T. et al. · European Journal of Pharmacology (2022)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Falchi, M., Wießner, I., Silva, S. R. B. et al. · European Neuropsychopharmacology (2024)
Show all 22 referencesShow fewer
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Holze, F., Duthaler, U., Vizeli, P. et al. · British Journal of Clinical Pharmacology (2019)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)
Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)
Vizeli, P., Studerus, E., Holze, F. et al. · Translational Psychiatry (2024)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Cited By (4)
Papers in Blossom that reference this study
Erne, L., Mueller, L., Straumann, I. et al. · Translational Psychiatry (2026)
Perkins, D., Halman, A., Urokohara, A. et al. · Scientific Reports (2025)
Äbelö, A., Smallridge, J. W., Von Rotz, R. et al. · Biomedicine & Pharmacotherapy (2025)
Zuiker, R. G. J. A., Otto, M. E., Bryan, C. S. et al. · Clinical and Translational Science (2025)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.